Analysis on the Efficacy of Tereprimab Combined with Cisplatin and Docetaxel Induced Chemotherapy for Locally Advanced Nasopharyngeal Cancer
Objective To study the efficacy of triplelizumab combined with cisplatin and docetaxel in the treatment of locally advanced nasopharyngeal carcinoma.Methods Forty-five patients with locally advanced nasopharyngeal carci-noma admitted to the First People's Hospital of Qinzhou City from January 2022 to September 2023 were non-randomly selected as research object,and divided into control group(n=22,cisplatin and docetaxel induction chemo-therapy)and observation group(n=23,combined with terprilizumab on the basis of control group)according to treat-ment methods.The clinical efficacy,the occurrence of adverse reactions and the level of T cell subsets were compared between the two groups.Results The total clinical objective remission rate of the observation group was 91.30%(21/23),higher than 59.09%(13/22)of the control group,the difference was statistically significant(χ2=6.318,P<0.05).CD4+and CD4+/CD8+in peripheral blood of the observation group were higher than those of the control group,and the differences were statistically significant(both P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(all P>0.05).Conclusion The combination of triplizumab,cisplatin and docetaxel in patients with locally advanced nasopharyngeal carcinoma can achieve ideal efficacy and high safety.
NETL
NSTL
万方数据
